K D N & ASSOCIATES LLP
Buying intent
20 tracked signals | Top 15 topics are below | HR is carrying most of it.
Attention by team
LinkedIn activity, by teamWhere K D N & ASSOCIATES LLP's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
15d ago
17d ago
5d ago
17d ago
15d ago
17d ago
5d ago
5d ago
17d ago
24d ago
5d ago
14d ago
15d ago
14d ago
15d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at K D N & ASSOCIATES LLP
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
Primary products / business lines
LinkedIn company profileAt Kedrion, we believe that innovation and care must go hand in hand. Our mission is to enhance lives through our dedicated work in the field of rare and ultra-rare diseases. As a global leader with a passionate team of 5,200 employees, we collect and fractionate plasma to produce and distribute 38 vital medicines worldwide, establishing ourselves as the fifth largest player in the plasma-derived
Top accounts researching K D N & ASSOCIATES LLP
names withheld on the public pageThese are companies whose own people brought up K D N & ASSOCIATES LLP unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
66,174 companies · 318,882 people are researching Hiring
K D N & ASSOCIATES LLP's own team shows 2 signals on this topic. No one outside K D N & ASSOCIATES LLP has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- International Tax536 cos · 1,721 people
- AI Marketing1,897 cos · 4,437 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)HR / Talent — 1 person
What's been said
public posts by K D N & ASSOCIATES LLP's teamNo public post naming K D N & ASSOCIATES LLP has surfaced in the past year, so this is what K D N & ASSOCIATES LLP's own team is posting about publicly — their topics, in their words.
Kedrion has been on a journey of growth and major transformation. Behind solid investments, there is always the work of many people: people who shape, support, and make the success of an organization possible every day. Our new HQ offices are a strong expression of this spirit: open spaces, no barriers, all functions brought together in one location, areas designed to share work, ideas, and collaboration, surrounded by a beautiful landscape. These offices tell the story of what Kedrion is today, and what Kedrion is becoming for tomorrow
May 2026Great to attend LogiPharma 2026 in Vienna last week, joining colleagues from across the global pharmaceutical supply chain ecosystem. A few reflections: • AI is now everywhere; with a clear shift towards agentic applications supporting more autonomous and real-time decision-making. • End-to-end visibility is no longer an ambition but a structural requirement to build resilient and responsive pharma networks. • Sustainability continues to reshape logistics trade-offs, alongside compliance and cost - not as a separate agenda, but as an integrated one. Good to exchange perspectives and ideas with peers, and to hear how these themes are being addressed across different regions and organizations. #Pharma #SupplyChain #Logistics
Apr 2026GSK calling blockbuster potential on an early-stage oncology asset caught my attention. Big pharma usually waits. Phase 3. Registrational clarity. Here, they’re leaning in early. That says two things: - internal confidence is likely strong - but also: the game has changed In oncology today, if you wait too long to position an asset, you’re already behind — on valuation, on partnering, on narrative. We’re seeing more companies “claiming the space” early, especially in targeted therapies where differentiation can emerge quickly. Source: https://lnkd.in/d5CQETYQ
Apr 2026